Hinge Health, Inc. (HNGE) said its Chief Financial Officer, James Budge, sold 10,906 shares of Class A common stock on March 23, 2026, for an aggregate of about $465,138.
The disposals were carried out in three distinct trades. Company filings indicate the overall set of transactions recorded prices ranging from $41.2858 to $42.8023. The first transaction consisted of 1,988 shares with executed prices between $40.73 and $41.69. The second transaction comprised 8,346 shares sold at prices between $41.78 and $42.77. The final tranche included 672 shares, executed at prices in the $42.78 to $42.87 band.
Context on ownership and market position
After these sales, Budge retains direct ownership of 401,427 Hinge Health shares. The company’s stock is trading at approximately $40.91, reflecting a year-to-date decline of roughly 12%.
Despite the pullback in the share price, InvestingPro analysis mentioned in company disclosures suggests Hinge Health may still be undervalued at current levels. The firm carries a market capitalization of $3.32 billion.
Recent financials and expectations
Hinge Health reported a loss of $7.77 per share over the last twelve months, according to the disclosure. Analysts, however, project a material recovery, forecasting earnings of $2.12 per share for fiscal 2026. Revenue in the most recent reporting period increased by 51% to $588 million.
Transaction mechanics
The sales were executed under a pre-existing Rule 10b5-1 trading plan that Budge adopted on June 12, 2025. The filing does not indicate any further trades or modifications to that plan in connection with the March activity.
Analyst and corporate developments
Several brokerages and research houses have updated their views on Hinge Health recently, showing a wide range of opinions and price targets. RBC Capital increased its target to $55 and kept an Outperform rating after investor meetings highlighting growth drivers including HingeSelect, AI developments, and geographical expansion. Truist Securities reiterated a Buy rating with a $63 price target following a favorable review of fourth-quarter 2025 results and discussions with management.
Barclays trimmed its price target to $52 but retained an Overweight rating, citing improved billings and higher engagement from new clients. Jefferies initiated coverage with a Hold rating and set a price target of $17.50. In governance news, Hinge Health added Tyler Sloat, CFO and COO of Freshworks Inc., to its board of directors.
What this means
The filings document a routine insider sale executed through an established trading plan and leave Budge with a substantial retained stake. The company’s recent revenue acceleration contrasts with a trailing loss per share and a spectrum of analyst valuations and ratings, underscoring differing assessments of Hinge Health’s near-term profitability trajectory and long-term market potential.